ClinicalTrials.gg
Status unknownNCT05513976Updated Aug 24, 2022

Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

A Phase 2 interventional study of SHR4640 tablet and SHR4640 tablet in Primary Gout and Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ruzinurad in Hyperuricemia — 1 open to participants now, 1 under way, none of them phase 3. ruzinurad · Hyperuricemia.

Planned enrollment
3rd of 11
129 · median 34
Started
2022
the only one that year
Phase 2
3 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
10 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing ruzinurad in Hyperuricemia, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 2, and was the 7th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 11 studies testing ruzinurad in Hyperuricemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ruzinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ruzinurad in Hyperuricemia, or all of them as a file.
02

Study summary

SHR4640 tablets is a highly selective and potent URAT1 inhibitors,study number is SHR4640-203. The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and febuxostat compared with placebo and febuxostat in primary gout and hyperuricemia subjects with inadequate control on febuxostat for 12 weeks.

03

Conditions studied

  • Primary Gout and Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed the , understood the procedures and methods of the study, and was willing to complete the study strictly in accordance with the clinical trial protocol;
  2. The screening age should be 18-65 years old (including both ends), male or female; 3. Receiving febuxostat dose ≥40mg/ day, not more than 80mg/ day, stable dose for ≥6 weeks, fasting serum uric acid ≥390µmol/L at screening; 4. Meet the 1977 or 2015 American College of Rheumatology (ACR) criteria for classification of gout; 5、18kg/m2≤ Body weight Mass index () ≤35kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. General Situation:

      1. Pregnant or lactating women;
      1. Refusal or use of medically unapproved measures by fertile women or men (except for non-fertile partners) within 3 months of screening to the last medication for men and 6 months for women;
      1. The average daily alcohol intake in the 1 month prior to screening was more than 14g (e.g., 145mL wine, 497mL beer, or 43mL low-alcohol liquor) for women and more than 28g (e.g., 290mL wine, 994mL beer, or 86mL low-alcohol liquor) for men;
      1. Drug abusers;
      1. Subjects whose compliance is considered by the investigator to be poor and affect the evaluation of the safety and efficacy of the trial drug.
  2. The following conditions occurred in the laboratory examination within 3 weeks before randomization:

      1. upper limit of (ALT) and/or aspartate aminotransferase (AST) and/or total (T-Bil);
      1. Serum creatinine was calculated using simplified Diet adjustment for Kidney Disease () formula and eGFR was less than 45mL/ (min×1.73m2).
      1. Glycosylated () ≥8%;
      1. Having active [hepatitis B surface antigen (HBsAg) positive and HBV deoxyribonucleic acid (HBV-DNA) ≥500 IU/mL or 2500 copies/mL], or anti- virus (HCV) antibody positive, or (HIV) antibody positive, Or a positive syphilis antibody test;
      1. White blood cell \< 3.0×109/L, and/or hemoglobin \< 90 g/L, and/or \< 80×109/L.
  3. Any of the following medical history or comorbidities:

      1. Allergy, allergy to SHR4640 or any component of SHR4640, or previous intolerance to febuxostat or ;
      1. Secondary hyperuricemia caused by tumors, chronic kidney diseases, blood diseases, drugs and other reasons;
      1. There are other joint lesions that researchers believe may confuse gouty arthritis, such as rheumatoid arthritis, pyogenic arthritis, traumatic arthritis, psoriatic arthritis, pseudogout, systemic lupus erythematosus, or joint lesions caused by chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy, etc.
      1. Urinary calculi were detected or suspected by B-ultrasound within 3 weeks before randomization;
      1. Gout attack within 2 weeks before randomization;
      1. History of active peptic ulcer within 1 year before screening or active peptic ulcer at screening;
      1. History of xanthine urine;
      1. The presence of , or a history of malignancy within 5 years prior to screening (except for treated non-melanoma of the skin without signs of recurrence, and resected cervical intraepithelial neoplasia);
      1. History of chronic infection or recurrent infection within 1 year before screening; Or a serious infection (including but not limited to hepatitis, sepsis, pneumonia, pyelonephritis, etc.) or infection leading to hospitalization in the 3 months prior to screening; Or an infection that was treated with intravenous antibiotics before screening; Or open draining wounds or ulcers at the time of screening;
      1. Patients who need to use agents for systemic therapy;
      1. Moderate to severe congestive heart failure ( class III or IV);
      1. Myocardial infarction, unstable angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, brain infarction, cerebral hemorrhage, subarachnoid hemorrhage, or , and other cardiovascular and cerebrovascular events leading to hospitalization occurred within 1 year before screening;
      1. Poorly controlled hypertension [systolic blood pressure (SBP) ≥180mmHg and/or diastolic blood pressure (DBP) ≥110mmHg at rest, reconfirmed];
      1. combined with other serious or poorly controlled diseases;
      1. Patients who had undergone major surgery within 3 months prior to surgery, or had not recovered from surgery, or planned to undergo major surgery during the study period;
      1. Blood donation (or blood loss) and blood donation (or blood loss) ≥400 mL within 3 months before screening, or receiving blood transfusion.
  4. Use any of the following drugs or participate in clinical trials:

      1. Participated in any drug (including investigational vaccine) clinical trial and used investigational drug within 3 months before screening or within the half-life of 5 investigational drugs (whichever is longer);
      1. Participated in any clinical trial of medical device within 3 months prior to screening (excluding failed screening subjects);
      1. Use other uric acid lowering drugs (allopurinol, benzbromarone, and recombinant uricase) within 6 weeks before screening;
      1. Drugs that interact with febuxostat (theophylline, azathioprine, mercaptopurine) were used within 6 weeks before screening;
      1. Within 6 weeks before screening, the daily dose of aspirin was more than 100mg or the dose was unstable;
      1. Use any diuretic within 2 weeks before randomization;
      1. Blood pressure, lipid-lowering and glucose-lowering drugs with unstable dose were used within 2 weeks before randomization.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (estimated)

Study arms

  • Experimental
    treatment group A

    Drug: SHR4640 tablet · Drug: febuxostat tablet

  • Experimental
    treatment group B

    Drug: SHR4640 tablet · Drug: febuxostat tablet

  • Placebo comparator
    treatment group C

    Drug: febuxostat tablet · Drug: SHR4640 placebo tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with serum uric acid ≤360μmol/L

    Time frame: After 12 weeks of treatment

Secondary outcomes

  1. Proportion of subjects with serum uric acid ≤ 300μmol/L (response)

    Time frame: After 12 weeks of treatment

  2. Proportion of subjects with serum uric acid ≤360μmol/L at the last two tests at 12 weeks of double-blind treatment

    Time frame: After 12 weeks of treatment

  3. Percentage change in serum uric acid from baseline at each visit

    Time frame: within 12 weeks of double-blind treatment

  4. Changes in serum uric acid from baseline at each visit

    Time frame: within 12 weeks of double-blind treatment

  5. Proportion of subjects with serum uric acid ≤360μmol/L at each visit

    Time frame: within 12 weeks of double-blind treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2022; primary completion for May 2023, 8 months later.

Of 24 phase 2 interventional studies under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartEst.
Sep 15, 2022
Primary completionEst.
May 30, 2023
CompletionEst.
Sep 20, 2023
Last update
Aug 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05513976
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Sep 15, 2022 (estimated)
Primary completion
May 30, 2023 (estimated)
Completion
Sep 20, 2023 (estimated)
Last update
Aug 24, 2022

Study contacts

Wangwang Zhi
Contact
Wangwang.zhi@hengrui.com.cn
+86 18036618683

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion